| Bioactivity | BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research[1]. |
| Invitro | BKIDC-1553 (1.25-20 μM, 72 h) 在多种人前列腺癌细胞株中剂量依赖性地抑制细胞增殖[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BKIDC-1553 相关抗体: |
| In Vivo | BKIDC-1553 (20 mg/kg, 口服，每周 3 次，共 4 周) 在 5 周后降低 LuCaP 35 人前列腺癌患者来源的异种移植小鼠的肿瘤生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 1951431-34-7 |
| Formula | C22H23N5O2 |
| Molar Mass | 389.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Uo T, et al. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. bioRxiv [Preprint]. 2024 Feb 13:2023.07.01.547355. |
BKIDC-1553
CAS: 1951431-34-7 F: C22H23N5O2 W: 389.45
BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.